St. Jude Stock Tumbles On T-Wave Alternans Coverage; Index Continues Slide

This article was originally published in The Gray Sheet

10 Apr 2006
News

Executive Summary

St. Jude Medical's stock ended the 2006 first quarter down 18% to $41 per share following CMS' decision to reimburse a device that can identify patients who are unlikely to benefit from an implantable cardioverter defibrillator, St. Jude's bread and butter

Existing Subscriber? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT023427

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT023427

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

St. Jude Stock Tumbles On T-Wave Alternans Coverage; Index Continues Slide

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

St. Jude Stock Tumbles On T-Wave Alternans Coverage; Index Continues Slide

News

Executive Summary

Related Content

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert